Get started
Work

The role of fMRI in drug development

Year: 2017
Type: review
Abstract: Functional magnetic resonance imaging (fMRI) has been known for over a decade to have the potential to greatly enhance the process of developing novel therapeutic drugs for prevalent health conditions. However, the use of fMRI in drug development continues to be relatively limited because of a variety of technical, biological, and strategic barriers that continue to limit progress. Here, we briefly review the roles that fMRI can have in the drug development process and the requirements it must meet to be useful in this setting. We then provide an update on our current understanding of the strengths and limitations of fMRI as a tool for drug developers and recommend activities to enhance its utility.
DOI: 10.1016/j.drudis.2017.11.012
Authors: Owen Carmichael, Adam J. Schwarz, Christopher H. Chatham, David Scott, Jessica A. Turner, Jaymin Upadhyay, Alexandre Coimbra, James A. Goodman, Richard Baumgartner, Brett A. English, John W. Apolzan, Preetham Shankapal, Keely R. Hawkins
Institutions: Pennington Biomedical Research Center, Eli Lilly (United States), F. Hoffmann-La Roche AG, BioClinica (United States), Georgia State University, Regeneron (United States), Genentech, Pfizer (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Dart NeuroScience (United States)
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,720
Funders: Pennington Biomedical Research Foundation, Merck, Takeda Pharmaceuticals U.S.A., National Institutes of Health, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Biomedical Imaging and Bioengineering
OpenAlex ID: W2768984775
FWCI: 0.826
Cites: 242
Cited by: 62
Related to: 10